Ask AI
ProCE Banner Activity

DeLLphi-303: Phase Ib Study of 1L SoC Chemoimmunotherapy + Tarlatamab in Extensive-Stage Small-Cell Lung Cancer

Conference Coverage
Slideset

In the phase Ib DeLLphi-303 study of tarlatamab combined with standard of care first-line chemoimmunotherapy and anti–PD-L1 maintenance therapy, tarlatamab demonstrated a manageable safety profile and encouraging efficacy outcomes in patients with ES-SCLC.

Released: October 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly